Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Chloroform. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 7/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Chloroform SCHEMBL8192102 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL8927142 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL8196816 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL7542885 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL35119 | 1.00 | — | — | |
| Chloroform SCHEMBL7768433 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL8927139 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL2819782 | 1.00 | TSHR (0.60) | TSHRALDH1A1LMNATDP1TP53 | |
| Chloroform SCHEMBL2118727 | 0.95 | — | — | |
| Chloroform SCHEMBL6974119 | 0.95 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492373-B2 | FOR TREATMENT OF BACTERIAL INFECTIONS AND/OR RENAL CANCER DISEASES | PHARMACEUTICAL INDUSTRY TECHNOLOGY AND DEVELOPMENT CENTER (TW) | 2002-12-10 | — | — | US | disclosed |
| US-20020061895-A1 | 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions | PHARMACEUTICAL INDUSTRY TECHNOLOGY | 2002-05-23 | — | — | US | disclosed |
| EP-0271829-B1 | DELTA-HYDROXY-BETA-LYSINE DERIVATIVES AND THEIR PRODUCTION | Takeda Chemical Industries, Ltd. (JP) | 1993-08-25 | — | — | EP | disclosed |
| US-4906659-A | Antibiotic tan-749, its derivatives, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061895-A1 | 6-fluoro-1,4-dihydro-7-[4-(2-hydroxyiminoethyl)-1-piperazinyl]-4-oxoquinoline-3-carboxylic acid derivatives, their preparation and pharmaceutical compositions | ATP6V1B1, GLS, RCC2 | TSHR 4835/4885ALDH1A1 234/4885LMNA 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.